All Articles

New research shows soaring housing costs are pushing residents out, creating an urgent economic and social challenge that state leaders are scrambling to address.

AM Best's top-tier rating affirms National Life Group's market strength, but a deeper look reveals a strategy balancing aggressive growth with complex challenges.

Korean firm Wooree Green Science enters the U.S. with LipoPrime™, betting that measurable quality and scientific proof can win in a crowded market.

XbotGo's landmark deal with Best Buy isn't just a retail win; it's a signal that AI is finally becoming the ultimate tool for the modern family.

XChange TEC's plan to acquire AI firm First Cycle reveals a bold strategy to automate insurance from the ground up, moving beyond distribution to core operations.

Lucid Diagnostics reports rising revenue and a key insurance win for its EsoGuard test, but its financial future hangs in the balance of a pivotal Medicare decision.

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.

Despite a sharp performance dip in July driven by an AI stock selloff, investors continue to pour capital into hedge funds for the seventh straight month.

Lurie Children's new facility is more than a pharmacy; it's a look into a new system where hospitals integrate business and care to survive and thrive.

LightInTheBox secures $5.49M for an AI overhaul, with its CEO personally investing $1.09M. Is this the catalyst needed to thrive in a crowded market?

Beyond the polish, the rise of companies like Pudu Robotics reveals the real story: an AI-driven digital infrastructure is quietly rewiring our cities.

FlightHub's new AI assistant, PAX, aims to find hidden travel deals. But as it scans for bargains, the company must also navigate a history of turbulence.

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

A startup's revolutionary 'space sling' just won a massive Space Force contract. Here's why this fuel-free platform could redefine orbital warfare.

A private equity firm's acquisition of a wastewater company reveals a deeper story about water scarcity, reshoring, and the systems we need to thrive.

As CEO Gareth Sheridan takes the stage, his company's abuse-deterrent tech, AVERSA™, promises a new front in the opioid crisis. But can it deliver?

With a blockbuster IPO and dazzling growth, Bending Spoons looks unstoppable. But a closer look reveals a high-stakes strategy built on massive debt.

SPXChart's new platform promises to show everyday traders the market's hidden plumbing. But can it truly level the playing field against Wall Street's titans?

Kolibri Global Energy shatters records with a 109% revenue jump, but the real story lies underground with a new strategy to unlock vast, untapped reserves.